We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Alon Harris

Alon Harris MS, PhD, FARVO

Lois Letzter Endowed Chair in Ophthalmology, Professor of Ophthalmology, Professor of Cellular and Integrative Physiology, Director, Glaucoma Research and Diagnostic Center, Department of Ophthalmology, Indiana University School of Medicine, Indianapolis, Indiana, USA

Professor Alon Harris is a world expert and leader in the field of ocular blood flow. He is an internationally recognized clinical researcher focusing on glaucoma risk factor assessment, monitoring techniques for structural and functional glaucoma progression, ocular perfusion assessment, glaucoma medications, generic medications, imaging methodologies and population based studies.

Professor Harris founded and established one of the world’s leading centers for ocular blood flow and its implications to glaucoma, diabetic retinopathy, age-related macular degeneration and non-arteritic ischemic optic neuropathy at the Indiana University School of Medicine. He has published over 330 peer-reviewed journal articles, 18 books and more than 40 book chapters.

Professor Harris has received numerous national and international awards including the Sam Rothberg Glaucoma Award; the William and Mary Greve International Research Scholar Award from the Research to Prevent Blindness organization; the Glenn W. Irwin Jr., MD., Experience Excellence Recognition Award; Edmund Benjamin Spaeth Oration Award for Outstanding Clinical Research; American Academy of Ophthalmology Achievement Award and Letzter Endowed Chair of Ophthalmology

 

Disclosures

This investigation was supported by NIH 1R21EY022101-01A1. There are no conflixts of interest. Dr. Alon Harris would like to disclose that he receives remuneration from Stemnion, Biolight, Nano Retina, AdOM, Science Based Health, Isarna Therapeutics, and Ono Pharmaceuticals for serving as a consultant. Dr. Harris also holds an ownership interest in AdOM, Nano Retina, and Oxymap. All relationships listed above are pursuant to Indiana University’s policy on outside activities.

Professor Harris has received over 5 million dollars in research funds from prestigious institutions including the National Institutes of Health, National Science Foundation, American Diabetes Association, and the National Eye Institute in the United States.

Professor Harris holds two patents related to ocular blood flow: 1) Novel Treatment of Macular Edema; and 2) Method to Increase Retinal and Optic Nerve Head Blood Flow.